SAN DIEGO, Dec. 9, 2016 /PRNewswire/ -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced that senior management will participate in a fireside chat at the upcoming BMO Prescriptions for Success Healthcare Conference at the InterContinental Barclay Hotel in New York City on Wednesday, December 14, 2016, at 4:20 p.m. ET.
About aTyr Pharma
aTyr Pharma is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological modulators. The Company's lead candidate, Resolaris™, is a potential first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component. Resolaris is currently in a Phase 1b/2 trial in adult patients with limb-girdle muscular dystrophy 2B (LGMD2B or dysferlinopathies) or FSHD and a Phase 1b/2 trial in patients with an early onset form of FSHD. In addition, Resolaris is currently being evaluated in two Phase 1b/2 long-term safety extension studies, the first in patients with adult FSHD and the second in patients with LGMD2B, adult FSHD or early onset FSHD. To protect this pipeline, aTyr has built an intellectual property estate comprising over 80 issued or allowed patents and over 230 pending patent applications that are owned or exclusively licensed by aTyr, including over 300 potential Physiocrine-based protein compositions. aTyr's key programs are currently focused on severe, rare diseases characterized by immune dysregulation for which there are currently limited or no treatment options. For more information, please visit http://www.atyrpharma.com.
Sr. Director, Investor Relations
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/atyr-pharma-to-present-at-the-bmo-prescriptions-for-success-healthcare-conference-300375951.html
SOURCE aTyr Pharma, Inc.